ENhanced Recovery and ABbreviated LEngth of Anticoagulation for Thromboprophylaxis After Primary Hip Arthroplasty

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2932 participants.

Also called NCT06611319

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 2,932 participants (planned count) (from the registry)
Sponsor
Prof. Stavros Konstantinides, MD (from the registry)
Registry
  • NCT NCT06611319
  • EU CT 2023-507490-18-00
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Austria, Germany (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06611319. Randomized; quadruple masking; primary purpose prevention. Start 2024-11-26 (actual); primary completion 2027-03 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
ENhanced Recovery and ABbreviated LEngth of Anticoagulation for Thromboprophylaxis After Primary Hip Arthroplasty
Acronym
ENABLE-Hip
Condition
Hip Arthroplasty, Total
Condition
Prevention of Venous Thromboembolism
Intervention (Drug)
Prevention of Venous Thromboembolism
Intervention (Drug)
Placebo Oral Tablet
Lead sponsor
Prof. Stavros Konstantinides, MD (class: other)

Record details

Record id
cardio:ct-nct06611319
Content hash
c3bd036e68713be9fd73cfd17ba4178d2599dad23a3be9f3345a4eedb0de70a7